Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Immunodeficiency Clinic, University Health Network, University of Toronto, 200 Elizabeth Street, Toronto, Canada M5G 2C4. bob.burgoyne@uhn.on.ca
Advances in highly active antiretroviral therapy (HAART) options for people living with HIV/AIDS have resulted in decreased morbidity and mortality. To some extent, the role of disease progression in eroding quality of life (QOL) erosion in the pre-HAART age is now supplanted by drug toxicities, one of the Achilles' heels of HAART. This article reviews research findings on treatment and QOL outcomes a decade into the HAART era.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on